STOCK TITAN

Oramed grants Yehuda Reznick 72,780 Board shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

ORAMED PHARMACEUTICALS INC. director Yehuda Reznick received two restricted stock awards on November 12, 2026: 72,780 shares for annual Board awards covering fiscal years 2027 and 2028, and 2,890 shares for fiscal year 2027 committee awards. The Board award vests in 12 substantially equal quarterly installments beginning April 1, 2027 and April 1, 2028, respectively; the committee award vests in four substantially equal quarterly installments beginning April 1, 2027. Both awards are subject to continued service. The issuer stated that no annual Board award will be granted to Reznick for fiscal year 2028.

Insider Reznick Yehuda
Role Director
Type Security Shares Price Value
Grant/Award Common Stock F1 72,780 -- --
Grant/Award Common Stock F2 2,890 -- --
Holdings After Transaction: Common Stock — 180,850 shares (Direct)
Holdings Before and After: Common Stock, 105,180 to 180,850 shares (Direct)
Footnotes (2)
  1. F1. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 72,780 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual Board awards for fiscal years 2027 and 2028. Of these shares, 36,390 vest in twelve substantially equal quarterly installments beginning April 1, 2027, and 36,390 vest in twelve substantially equal quarterly installments beginning April 1, 2028, in each case subject to the reporting person's continued service. No annual Board award will be granted to the reporting person for fiscal year 2028.
  2. F2. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 2,890 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's fiscal year 2027 committee awards, which vest in four substantially equal quarterly installments beginning April 1, 2027, subject to the reporting person's continued service.
Restricted stock award 72,780 shares Annual Board awards covering fiscal years 2027 and 2028; granted November 12, 2026
Committee award 2,890 shares Fiscal year 2027 committee awards; granted November 12, 2026
restricted stock award financial
"restricted stock award of 72,780 shares"
A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.
substantially equal quarterly installments financial
"vest in twelve substantially equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORMP shares did Yehuda Reznick receive in his November 2026 awards?

Yehuda Reznick received a 72,780-share restricted stock award for annual Board awards covering fiscal years 2027 and 2028, plus a separate 2,890-share award for fiscal year 2027 committee awards, on November 12, 2026.

How do Yehuda Reznick's ORMP stock awards vest?

The 72,780-share Board award is split into two 36,390-share portions, each vesting in 12 substantially equal quarterly installments beginning April 1, 2027 and April 1, 2028, respectively; the 2,890-share committee award vests in four substantially equal quarterly installments beginning April 1, 2027, with both awards subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reznick Yehuda

(Last)(First)(Middle)
1185 AVENUE OF THE AMERICAS
THIRD FLOOR

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026A72,780(1)A(1)177,960D
Common Stock11/12/2026A2,890(2)A(2)180,850D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 72,780 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual Board awards for fiscal years 2027 and 2028. Of these shares, 36,390 vest in twelve substantially equal quarterly installments beginning April 1, 2027, and 36,390 vest in twelve substantially equal quarterly installments beginning April 1, 2028, in each case subject to the reporting person's continued service. No annual Board award will be granted to the reporting person for fiscal year 2028.
2. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 2,890 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's fiscal year 2027 committee awards, which vest in four substantially equal quarterly installments beginning April 1, 2027, subject to the reporting person's continued service.
/s/ Yehuda Reznick11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading